{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:25:34Z","timestamp":1791890734578,"version":"4.3.4"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the impact of doxycycline post-exposure prophylaxis (DoxyPEP) on Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and syphilis (SPL) incidence in a high-risk MSM cohort in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>HIV pre-exposure prophylaxis (PrEP) users at high risk of sexually transmitted infections (STIs) seen in our clinic between March 2023 and August 2024 were offered DoxyPEP. The incidence of the first CT, NG and SPL episode was compared between pre-DoxyPEP and post-DoxyPEP periods using Cox proportional hazard models. NG and MDR bacteria cultures were also conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 876 PrEP users, 197 (22.4%) were eligible and initiated DoxyPEP; 98.4% were MSM. Incidence rates per 100 people per year for the first STI episode in the pre- and post-DoxyPEP periods were: 31.4 and 7.8 (P\u200a=\u200a0.0001) for CT, 41.5 and 28.9 (P\u200a=\u200a0.1) for NG, and 21.5 and 3.2 (P\u200a=\u200a0.0001) for SPL. NG culture was positive in 14 (29.7%) of 47 NG infections detected by PCR in the post-DoxyPEP period. All isolates were sensitive to ceftriaxone, and resistance to tetracyclines was similar to those not on DoxyPEP (42.7% versus 46.3%, P\u200a=\u200a0.23). DoxyPEP was discontinued in nine (4.5%) participants. Prevalence of MDR bacteria was similar at baseline and at 48\u2005weeks (10.6% versus 8.2%; P\u200a&amp;gt;\u200a0.5).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DoxyPEP was well accepted within routine PrEP care, significantly reducing STI incidence with good tolerance. Our data show its efficacy and safety in real-world settings. The emergence of MDR bacteria or resistant NG was not observed. However, its impact on bacterial resistance and the microbiota requires further evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf366","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:57:11Z","timestamp":1757591831000},"page":"3306-3310","source":"Crossref","is-referenced-by-count":6,"title":["Post-exposure prophylaxis with doxycycline (DoxyPEP) to prevent STIs in a real-world setting: the PRIDOX study"],"prefix":"10.1093","volume":"80","author":[{"given":"R","family":"Palacios","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, Hospital Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA) , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"G\u00f3mez-Ayerbe","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA) , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Mart\u00edn-Cort\u00e9s","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA) , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Gonz\u00e1lez-Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"ECAI Bioinform\u00e1tica, Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA) , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"L\u00f3pez-J\u00f3dar","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA) , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I A","family":"P\u00e9rez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA) , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4354-8418","authenticated-orcid":false,"given":"J","family":"Santos","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, Hospital Virgen de la Victoria , M\u00e1laga ,","place":["Spain"]},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de M\u00e1laga (IBIMA) , M\u00e1laga ,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025120206223161100_dkaf366-B1","author":"European Centre for Disease Prevention and Control (ECDC)"},{"key":"2025120206223161100_dkaf366-B2","author":"Unidad de vigilancia de VIH, ITS y hepatitis B y C"},{"key":"2025120206223161100_dkaf366-B3","volume-title":"Implementing the global health sector strategies on HIV, viral hepatitis and sexually transmitted infections, 2022\u20132030: report on progress and gaps 2024","author":"World Health Organization","year":"2024"},{"key":"2025120206223161100_dkaf366-B4","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/S1473-3099(17)30725-9","article-title":"Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial","volume":"18","author":"Molina","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025120206223161100_dkaf366-B5","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa2211934","article-title":"Postexposure doxycycline to prevent bacterial sexually transmitted infections","volume":"388","author":"Luetkemeyer","year":"2023","journal-title":"N Engl J Med"},{"key":"2025120206223161100_dkaf366-B6","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1016\/S1473-3099(24)00236-6","article-title":"Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2\u2008\u00d7\u20082 factorial design","volume":"24","author":"Molina","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025120206223161100_dkaf366-B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11904-024-00709-w","article-title":"Doxycycline post-exposure prophylaxis for bacterial sexually transmitted infections: the current landscape and future directions","volume":"22","author":"Allan-Blitz","year":"2024","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025120206223161100_dkaf366-B8","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1001\/jamainternmed.2024.7186","article-title":"Doxycycline postexposure prophylaxis and bacterial sexually transmitted infections among individuals using HIV preexposure prophylaxis","volume":"185","author":"Traeger","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2025120206223161100_dkaf366-B9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1001\/jamainternmed.2024.7178","article-title":"Doxycycline postexposure prophylaxis and sexually transmitted infection trends","volume":"185","author":"Sankaran","year":"2025","journal-title":"JAMA Intern Med"},{"key":"2025120206223161100_dkaf366-B10","doi-asserted-by":"publisher","first-page":"ofaf089","DOI":"10.1093\/ofid\/ofaf089","article-title":"Doxycycline postexposure prophylaxis for bacterial STIs: prescribing patterns, use, short-term outcomes among 2083 patients in a Los Angeles federally qualified health care program, and implications for widespread use","volume":"12","author":"Osmundson","year":"2025","journal-title":"Open Forum Infect Dis"},{"key":"2025120206223161100_dkaf366-B11","doi-asserted-by":"publisher","first-page":"100871","DOI":"10.1016\/j.lanepe.2024.100871","article-title":"High tetracycline resistance percentages in Neisseria gonorrhoeae in Europe: is doxycycline post-exposure prophylaxis unlikely to reduce the incident gonorrhoea cases?","volume":"38","author":"Unemo","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"2025120206223161100_dkaf366-B12","author":"Centers for Disease Control and Prevention"},{"key":"2025120206223161100_dkaf366-B13","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1007\/s10096-023-04601-0","article-title":"Epidemiology and antimicrobial resistance profile of Neisseria gonorrhoeae in Catalonia, Spain, 2016-2019","volume":"42","author":"Herrero","year":"2023","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2025120206223161100_dkaf366-B14","doi-asserted-by":"publisher","first-page":"dlac009","DOI":"10.1093\/jacamr\/dlac009","article-title":"A systematic review of the impacts of oral tetracycline class antibiotics on antimicrobial resistance in normal human flora","volume":"4","author":"Truong","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025120206223161100_dkaf366-B15","doi-asserted-by":"publisher","first-page":"e268","DOI":"10.1016\/S1473-3099(23)00359-6","article-title":"Selection of Neisseria gonorrhoeae ceftriaxone resistance using doxycycline post-exposure prophylaxis","volume":"23","author":"Whiley","year":"2023","journal-title":"Lancet Infect Dis"},{"key":"2025120206223161100_dkaf366-B16","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1093\/jac\/dkad129","article-title":"Important considerations regarding the widespread use of doxycycline chemoprophylaxis against sexually transmitted infections","volume":"78","author":"Kong","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025120206223161100_dkaf366-B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae062","article-title":"Filling in the gaps: updates on doxycycline prophylaxis for bacterial sexually transmitted infections","author":"Hazra","year":"2024; 062","journal-title":"Clin Infect Dis"},{"key":"2025120206223161100_dkaf366-B18","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41591-024-03274-2","article-title":"Impact of doxycycline post-exposure prophylaxis for sexually transmitted infections on the gut microbiome and antimicrobial resistome","volume":"31","author":"Chu","year":"2025","journal-title":"Nat Med"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3306\/65173669\/dkaf366.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3306\/65173669\/dkaf366.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:41Z","timestamp":1764674561000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3306\/8314016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,4]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf366","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,11,4]]}}}